Astrazeneca Ab

Scott Throner

James Empfield

James Jeffrey Folmer

Joseph Cacciola

Angela M Hunter

Andrew Griffin

Steven Sigmund Wesolowski

Denis Labrecque

Todd Andrew Brugel

Phil Edwards

James Arnold

Thierry Groblewski

Eifion D Phillips

Dean Brown

Disclosed herein is at least one cyclopropyl amide derivative, at least one pharmaceutical composition comprising at least one cyclopropyl amide derivative disclosed herein, and at least one method of using at least one cyclopropyl amide derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith.

Cyclopropyl amide derivatives

Compounds in accord with Formula I: wherein R, R, Rand Rare as defined in the specification, pharmaceutically acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.

Metabotropic glutamate receptor isoxazole ligands and their use as potentiators&#x2014;286

Metabotropic glutamate receptor isoxazole ligands and their use as potentiators

Metabotropic glutamate receptor isoxazole ligands and their use as potentiators 286

Compounds of formula I: wherein A and Rare as defined in the specification, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially in the treatment or prophylaxis of psychotic and intellectual impairment disorders.

4-substituted imidazoles

Growing community of inventors

Wilmington, DE, United States of America

Scott Throner